Format

Send to

Choose Destination
Neurol Sci. 2017 May;38(Suppl 1):201-206. doi: 10.1007/s10072-017-2916-7.

Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial.

Author information

1
Neurological and Stroke Unit Department, Headache Center, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Via Pio II, 3, 20153, Milan, Italy. paola.difiore@libero.it.
2
C. Besta Neurological Institute IRCCS Foundation and Igea Healthcare Institute, Milan, Italy.
3
Neurological and Stroke Unit Department, Headache Center, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, Via Pio II, 3, 20153, Milan, Italy.
4
Maxillo-Facial and Dental Unit, Dental and Oral Surgery, Headache and Facial Pain Center, IRCCS Foundation Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
5
LIMPE-DISMOV Academy, University La Sapienza, Rome, Italy.
6
Headache Center, Carlo Besta Neurological Institute and Foundation, Milan, Italy.

Abstract

Since chronic migraine is difficult to treat and often associated with medication overuse, non-invasive neurostimulation approaches are worth investigating. Transcutaneous supraorbital neurostimulation using the Cefaly® device is promising as a non-invasive preventive treatment for episodic migraine, but no data are available for chronic migraine. Our aim was to perform a preliminary evaluation of the efficacy of the Cefaly® device for the prophylaxis of chronic migraine with or without medication overuse. Primary endpoints were 50% reduction in monthly migraine days and 50% reduction in monthly medication use over 4 months. In an open-label study, twenty-three consecutive headache center patients with chronic migraine, diagnosed according to International Headache Society criteria, were recruited prospectively. After informed consent, patients were trained to use Cefaly® and instructed to use it for 20 min daily over 4 months. All patients received active neurostimulation. Thirty-five percent of the patients enrolled in the study achieved the study endpoints. Over half the patients had a greater than 50% reduction in acute medication consumption.

KEYWORDS:

Chronic migraine; Medication overuse; Migraine prophylaxis; Transcutaneous supraorbital neurostimulation

PMID:
28527053
DOI:
10.1007/s10072-017-2916-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center